Cost-effectiveness analysis of cholesterol-lowering therapies in Spain

American Journal of Cardiovascular Drugs

Volumn 6, Issue 3, 2006, Pages 177-188

  Plans Rubió, Pedro ^a,b  

^a General Direction of Public Health ^*  (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESTYRAMINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MALE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPAIN; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CHOLESTYRAMINE; CHOLESTYRAMINE RESIN; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LOVASTATIN; META-ANALYSIS; META-ANALYSIS AS TOPIC; PRAVASTATIN; PYRROLES; RISK FACTORS; SIMVASTATIN; SPAIN;

EID: 33745509213     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606030-00005     Document Type: Article

References (72)

1. Departament de Sanitat. Pla de salut de Catalunya 1999-2001. Barcelona: Departament de Sanitat, 1999
2. Departament de Sanitat. La salut i els serveis sanitaris a Catalunya. Barcelona: Departament de Sanitat, 2002
3. National Cholesterol Education Program. Executive summary of the third report of the expert committee on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
4. Wood D, de Backer G, Faergerman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-503
5. Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la colesterolemia en España, 2000: instrumento para la prevención cardiovascular. Clin Invest Arteriosclerosis 2000; 12: 125-52
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 individuals with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9
7. Sheperd J, Cobe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7
8. Downs J, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
9. Plans Rubió P. Impacto sobre el sistema sanitario catalán de la aplicación de las recomendaciones del segundo y tercer informes del National Cholesterol Education Program (ATP-II y ATP-III) sobre prevención y control de la hipercolesterolemia en adultos. Clin Invest Arteriosclerosis 2003; 15: 43-52
10. Hilleman DE, Phillips JO, Mohiuddin SM, et al. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Clin Ther 1999; 21: 536-62
11. Hilleman DE, Heineman SM, Foral PA. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 2000; 20: 819-22
12. Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzime A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol 1996; 78: 32-41
13. Vademecum Internacional. Madrid: Medicom SA, 2003
14. INSALUD. Informe económico-funcional de las Instituciones Sanitarias, 1987-110. Madrid: Ministerio de Sanidad y Consumo, 1992
15. Institut d'Estadística de Catalunya (IEC). Anuari estadístic 1992-2003. Barcelona: IEC, 2004
16. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin, a new HMG-CoA reductase inhibitor. Arch Intern Med 1998 Mar 23; 158: 577-84
17. Blum CB. Comparison and properties of four inhibitors of 3-hydroxy-3-methylglutaril-coenzyme A reductase. Am J Cardiol 1994; 73: 3-11D
18. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipemia: safety of treatment, changes in risk factors, and increased incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
19. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA 1984; 261: 351-64
20. Oberman A, Kreisberg RA, Henkin Y. Pharmacologic therapy of lipid disorders. In: Fisher M, editor. Principles and management of lipid disorders. London: Williams and Wilkins, 1992: 221-45
21. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford Uniuersity Press, 1996
22. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 810-5
23. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993; 71: 1408-14
24. Rindone JP, Hiller D, Arriola G. A comparison of fluvastatin 40mg every other day versus 20mg every day in patients with hypercholesterolemia. Pharmacotherapy 1998; 18: 836-9
25. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipo-protein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-86
26. Prisant LM, Downton M, Watkins LO, et al. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am J Cardiol 1996; 78: 420-4
27. Peters TK. Treatment of dyslipidaemias with fluvastatin. Br J Clin Pract Suppl 1996; 77A: 16-9
28. Banga JD, Jacotot B, Pfister P, et al. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study: French-Dutch Fluvastatin Study Group. Am J Med 1994; 96: 87-93S
29. Peters TK. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database. Am J Cardiol 1995; 76: 71-5A
30. Ose L, Davidson MH, Stein EA, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia: World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol 2000; 23: 39-46
31. Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 1996; 18: 853-63
32. Peters TK, Muratti EN, Mehra M. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk: an analysis of a clinical trial database. Am J Med 1994; 96: 79-83S
33. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 185-91
34. Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002; 22: 89-99
35. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002; 144: 1036-43
36. Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002; 287: 598-605
37. Karalis DG, Ross AM, Vacari RM, et al. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002; 89: 667-71
38. Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs 1999; 57: 583-606
39. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60
40. Haria M, McTavish D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53: 299-336
41. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9
42. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140-6
43. Henwood UM, Heel RC. Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988; 36: 429-54
44. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
45. Greten H, Beil FU, Schneider J, et al. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Am J Med 1994; 96 Suppl. 6A: 55-63S
46. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-9
47. Farmer JA, Washington LC, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia: The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther 1992; 14: 708-17
48. Zavoral JH, Haggerty BJ, Winick AG, et al. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: FLUENT Study Group: Fluvastatin Long-Term Extension Trial. Am J Cardiol 1995; 76: 37-40A
49. Davidson MH. Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med 1994; 96 Suppl. 6A: 41-S
50. Olsson AG, Eriksson M, Johnson O, et al. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther 2003; 25: 119-38
51. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994; 154: 1586-95
52. Jacotot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia: French Fluvastatin Study Group. Am J Cardiol 1995; 76: 54-6A
53. Jacotot B, Banga JD, Waite R, et al. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study): French-Dutch Fluvastatin Study Group. Am J Cardiol 1995; 76 (2): 41-6A
54. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after succesful coronary balloon angi-oplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1998; 20: 58-69
55. Bakker-Arkema RG, Best J, Fayyad R, et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997; 131: 17-23
56. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1248-52
57. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia: Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475-81
58. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44
59. Barter PJ, O'Brien RC. Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 2000; 149: 199-205
60. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin: a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82
61. Branchi A, Fiorenza AM, Rovellini A, et al. Lowering effects of four different statins on serum triglyceride level. Eur J Clin Pharmacol 1999; 55: 499-502
62. Black DM, Bakker-Arkema R, Heinonen T, et al. Does the presence of either cocurrent hypertension or non-insulin-dependent diabetes mellitus affect the efficacy and safety of atorvastatin in patients with hypercholesterolemia? Am J Hypertens 1998; 11: 75-9
63. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69
64. Harinder SM, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61: 1835-81
65. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16: 366-85
66. Data on file. Basel: Novartis Pharma AG
67. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61: 1835-81
68. Subdirección General de Asistencia y Prestación Farmacéutica. Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 2001. Información Terapéutica del Sistema Nacional de Salud 2002; 26: 78-83
69. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [publisher erratum appears in Am J Cardiol 1998 Jul 1; 82 (1): 128]. Am J Cardiol 1998 Mar 1; 81 (5): 582-7
70. Smith DG. The cost-effectiveness of statins: evidence from the ACCESS trial [abstract no. PVC37]. Value Health 2001; 4: 109
71. MacLaine GDH, Patel H. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels. Int J Clin Pract 2001; 55: 243-9
72. Koren MJ, Smith DG, Hunninghake DB, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics 1998; 14: 59-70